INGN at a glance
Inogen Inc (INGN, SEC CIK 1294133) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on September 30, 2026 and Form 4 insider filings as recently as September 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Inogen Inc (INGN) reported revenue of $295.3 million (up 5.9% from FY2024) and a net loss of $22.7 million. Diluted EPS was -$0.86.
- As of June 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Inogen Inc (INGN) shares worth $58.2 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Yi Boyer Jennifer M on July 1, 2026 of 10,938 shares at $6.60 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $295.3M
- +5.9% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 25 funds
- $58.2M · +0 vs prior quarter
- Latest 8-K
- Sep 30, 2026
- Item 8.01 · Item 7.01 · Item 1.01
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Repurchase authorization would rise from $30.0 million to $45.0 million upon Transaction closing
- Authorization extension through June 30, 2028, from December 31, 2027
Item 7.01: Regulation FD Disclosure
- Purchase Agreement with Rotech Healthcare, signaling a potentially material strategic transaction
- Separate product supply agreement creates an ongoing commercial relationship with Rotech
Item 1.01: Entry into a Material Definitive Agreement
- Inogen selling substantially all U.S. oxygen rental business assets to Rotech Healthcare
- Purchase price up to approximately $24.8 million, subject to post-closing reconciliation
Item EX-99.1: Item EX-99.1
- Divestiture of U.S. oxygen rental assets to Rotech for estimated cash consideration up to $25 million, expected closing Q4 2026
- Rental Business generated $24.3 million revenue in H1 2026, down 9.8% year over year
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release issued August 6, 2026
Item EX-99.1: Item EX-99.1
- Q2 revenue $95.1M, up 3.0% YoY, driven by international sales $41.3M, up 14.8%
- U.S. sales fell 2.3% and rental revenue fell 11.8%, highlighting continued domestic channel and rental-patient pressure
Item 7.01: Regulation FD Disclosure
- New Chief Operating Officer appointment announced July 1, 2026
- Leadership change may affect operating execution and strategic priorities
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Andy Reding appointed Executive Vice President and COO effective July 6, 2026, adding medical-device commercial and operations leadership
- Annual base salary $500,000 with target performance bonus opportunity equal to 70% of salary
Item EX-99.1: Item EX-99.1
- Andy Reding appointed Chief Operating Officer effective July 6, 2026, creating a new senior operating role
- COO mandate covers revenue growth, operational performance, cross-functional execution, and global expansion
AI summaries of INGN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for INGN
Don't miss the next INGN filing
- Alerts as it files. A push when INGN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut INGN, by share count.
- Ask anything. An AI agent that reads every INGN filing and answers with sources.
INGN alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Wright Mary E | A | Sep 1, 2026 | 1,500 | $5.33 |
| Smith Kevin P. | A | Sep 1, 2026 | 1,500 | $5.33 |
| Smith Kevin P. | M | Sep 1, 2026 | 18,136 | - |
| Smith Kevin Raymond Merrill | A | Sep 1, 2026 | 1,500 | $5.33 |
| Smith Kevin P. | F | Sep 1, 2026 | 8,671 | $5.33 |
| Smith Kevin P. | M | Sep 1, 2026 | 18,136 | - |
| Reding Andrew P. | A | Jul 6, 2026 | 130,000 | - |
| Yi Boyer Jennifer M | Sell | Jul 1, 2026 | 10,938 | $6.60 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $278.8M | $295.3M |
| Gross Profit | - | $154.7M | $154.3M |
| Operating Income | - | -$42.5M | -$30.2M |
| Net Income | - | -$35.9M | -$22.7M |
| Gross Margin | - | 55.5% | 52.2% |
| Op. Margin | - | -15.3% | -10.2% |
| Net Margin | - | -12.9% | -7.7% |
| Balance Sheet | |||
| Total Assets | $326.2M | $296.2M | $298.6M |
| Equity | $204.8M | $173.9M | $192.2M |
| ROE | - | -20.6% | -11.8% |
| Per Share | |||
| EPS | - | $-1.52 | $-0.86 |
| Cash Flow | |||
| Operating CF | - | $5.9M | -$11.2M |
| CapEx | - | $3.4M | $2.5M |
Source: XBRL data in Inogen Inc (INGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate INGN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 25 | $58.2M |
| Q1 2026 | 25 | $52.2M |
| Q4 2025 | 23 | $60.1M |
| Q3 2025 | 23 | $76.3M |
| Q2 2025 | 23 | $67.6M |
| Q1 2025 | 19 | $55.9M |
| Q4 2024 | 18 | $50.7M |
| Q3 2024 | 17 | $33.5M |
- AQR Capital Management+510.2K (+119%)
- Ameriprise Financial+123.5K (+14%)
- Morgan Stanley+105.1K (+19%)
- BlackRock+101.9K (+6%)
- JPMorgan Chase & Co+52.7K (+12%)
- Goldman Sachs Group−144.5K (-25%)
- Millennium Management−63.4K (-73%)
- Prudential Financial−40.1K (-11%)
- Dimensional Fund Advisors−21.2K (-4%)
- D.E. Shaw & Co−9.5K (-20%)
- Citadel Advisors LLC−176.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 173 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
INGN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 30, 2026 | - | Analysis | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | - | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jul 9, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 8-K | Jul 1, 2026 | - | Analysis | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 10-Q | May 8, 2026 | Mar 31, 2026 | - | |
| 8-K | May 7, 2026 | - | Analysis | |
| 4 | Apr 8, 2026 | - | - | - |
| 8-K | Apr 6, 2026 | - | Analysis | - |
| 8-K | Mar 30, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
Related Health Care companies
- ALGN · Align TechnologyOrthopedic, Prosthetic & Surgical Appliances & Supplies
- AVR · Anteris Technologies Global Corp.Orthopedic, Prosthetic & Surgical Appliances & Supplies
- AVNS · AVANOS MEDICAL, INC.Orthopedic, Prosthetic & Surgical Appliances & Supplies
- EW · Edwards LifesciencesOrthopedic, Prosthetic & Surgical Appliances & Supplies
- ENOV · Enovis CORPOrthopedic, Prosthetic & Surgical Appliances & Supplies
- ISRG · Intuitive SurgicalOrthopedic, Prosthetic & Surgical Appliances & Supplies
- LAKE · LAKELAND INDUSTRIES INCOrthopedic, Prosthetic & Surgical Appliances & Supplies
- MYO · MYOMO, INC.Orthopedic, Prosthetic & Surgical Appliances & Supplies
INGN SEC filings: frequently asked questions
Which institutions hold INGN stock?
As of June 30, 2026, the largest Inogen Inc (INGN) holders among the 13F filers tracked by SignalX were BlackRock ($11.3 million), Vanguard Capital Management LLC ($6.7 million), Ameriprise Financial ($6.3 million), AQR Capital Management ($6.0 million), Morgan Stanley ($4.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was INGN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Inogen Inc (INGN) reported revenue of $295.3 million (up 5.9% from FY2024) and a net loss of $22.7 million. Diluted EPS was -$0.86. The figures come from the XBRL data in the 10-K.
What did INGN report in its latest 8-K?
Inogen Inc (INGN) filed an 8-K on September 30, 2026 reporting Item 8.01 (Other Events), Item 7.01 (Regulation FD Disclosure) and Item 1.01 (Entry into a Material Definitive Agreement). Repurchase authorization would rise from $30.0 million to $45.0 million upon Transaction closing.
What are the latest INGN SEC filings?
Inogen Inc (INGN) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on September 30, 2026 and a Form 4 insider filing on September 3, 2026.
What is INGN's SEC CIK number?
Inogen Inc (INGN)'s SEC Central Index Key (CIK) is 1294133. EDGAR lists every INGN filing under that number.
Ask anything about INGN
The research agent reads INGN's filings, financials, insider trades and 13F holders, then answers with sources.